243 related articles for article (PubMed ID: 31440262)
1. Targeting Angiogenesis With Peptide Vaccines.
Rahat MA
Front Immunol; 2019; 10():1924. PubMed ID: 31440262
[TBL] [Abstract][Full Text] [Related]
2. Active Vaccination With EMMPRIN-Derived Multiple Antigenic Peptide (161-MAP) Reduces Angiogenesis in a Dextran Sodium Sulfate (DSS)-Induced Colitis Model.
Simanovich E; Brod V; Rahat MA
Front Immunol; 2018; 9():2919. PubMed ID: 30619283
[TBL] [Abstract][Full Text] [Related]
3. Peptide-Based Treatment: A Promising Cancer Therapy.
Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
[TBL] [Abstract][Full Text] [Related]
4. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
5. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
9. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
Tefit JN; Serra V
Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine.
Probst P; Stringhini M; Ritz D; Fugmann T; Neri D
Clin Cancer Res; 2019 Jan; 25(2):698-709. PubMed ID: 30327303
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
13. Getting peptide vaccines to work: just a matter of quality control?
Celis E
J Clin Invest; 2002 Dec; 110(12):1765-8. PubMed ID: 12488425
[No Abstract] [Full Text] [Related]
14. The Peptide Vaccine of the Future.
Nelde A; Rammensee HG; Walz JS
Mol Cell Proteomics; 2021; 20():100022. PubMed ID: 33583769
[TBL] [Abstract][Full Text] [Related]
15. [Advancement of peptide vaccines for hematologic malignancies].
Zhou WJ; He YJ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1512-7. PubMed ID: 22169315
[TBL] [Abstract][Full Text] [Related]
16. Peptides for Vaccine Development.
Hamley IW
ACS Appl Bio Mater; 2022 Mar; 5(3):905-944. PubMed ID: 35195008
[TBL] [Abstract][Full Text] [Related]
17. Vaccines targeting angiogenesis in melanoma.
Zahedipour F; Zamani P; Jamialahmadi K; Jaafari MR; Sahebkar A
Eur J Pharmacol; 2021 Dec; 912():174565. PubMed ID: 34656608
[TBL] [Abstract][Full Text] [Related]
18. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
19. Peptide-Based Cancer Vaccine Strategies and Clinical Results.
Schneble E; Clifton GT; Hale DF; Peoples GE
Methods Mol Biol; 2016; 1403():797-817. PubMed ID: 27076168
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
